Teva gets European OK to sell generic of Lilly's Evista

Back to TopCommentsE-mailPrintBookmark and Share

Teva Pharmaceutical Industries Ltd. won the backing of European drug regulators to sell a generic version of the Eli Lilly and Co. bone-loss drug Evista.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended allowing the Teva copy, known generically as raloxifene, to be sold to treat and prevent osteoporosis in women after menopause. The Israeli generic-drug maker’s product is equivalent to Evista, the agency said in a statement posted on its Web site Fridayday.

A court in September blocked Teva’s attempt to sell the drug in the United States before Lilly’s patents expire. The ruling protects Evista through March 2014, Indianapolis-based Lilly said at the time. Teva is appealing the ruling.

Evista generated $1.03 billion in sales last year, of which $348.1 million came outside the U.S., Lilly said on Jan. 28.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ